المؤلفون: D. Ross Camidge, MD, PhD, Fabrice Barlesi, MD, PhD, Jonathan W. Goldman, MD, Daniel Morgensztern, MD, Rebecca Heist, MD, MPH, Everett Vokes, MD, Eric Angevin, MD, PhD, David S. Hong, MD, Igor I. Rybkin, MD, Minal Barve, MD, Todd M. Bauer, MD, Angelo Delmonte, MD, Martin Dunbar, DrPH, Monica Motwani, PhD, Apurvasena Parikh, PhD, Elysa Noon, PhD, Jun Wu, MD, Vincent Blot, PhD, Karen Kelly, MD

المصدر: JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100262- (2022)

مصطلحات موضوعية: c-Met, Antibody-drug conjugate, Non–small cell lung cancer, Telisotuzumab vedotin, Nivolumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364321001211; https://doaj.org/toc/2666-3643

URL الوصول: https://doaj.org/article/5db379369d064b09bb9b7152b523f622